One taker in four years, but MHRA/NICE persist on parallel advice
This article was originally published in Scrip
Regulators and health technology assessors in the UK are trying to breathe life into a program that is aimed at providing drug companies with parallel scientific advice on their product development plans but which has only been used once in the more than four years it has been available.
You may also be interested in...
Sanofi failed in its attempt to have its EU marketing authorization application for avalglucosidase alfa fast-tracked through the centralized review process at the European Medicines Agency. This and other developments relating to the agency's accelerated assessment mechanism are logged in this latest update to the Pink Sheet's EU accelerated assessment tracker.
Change in leadership at the European Medicines Agency comes at a critical time.
The change in leadership at the European Medicines Agency comes at a critical time.